MUSC and Revival Forge New Model for MedTech Innovation

CHARLESTON, SC – April 29, 2026 – The Medical University of South Carolina (MUSC) and Revival Healthcare Capital have launched a five-year strategic partnership designed to fundamentally accelerate the journey of next-generation medical technologies from the laboratory to the patient bedside. The collaboration aims to create a streamlined and repeatable process for evaluating, developing, and advancing innovative medical devices.

A New Blueprint for Innovation

This partnership establishes a powerful synergy between one of the nation's leading academic health systems and a specialized MedTech investment firm. Under the agreement, MUSC's deep bench of clinicians and subject-matter experts will provide critical clinical and procedural insights, helping to vet and refine technologies aligned with Revival’s investment strategy. In turn, Revival Healthcare Capital brings not just funding but a hands-on operational model to guide promising technologies through the complex commercialization process.

“We are pleased to partner with MUSC to create a repeatable, high-velocity collaboration model that supports our investment strategy and our portfolio companies,” said Todd M. Pope, a senior partner at Revival Healthcare Capital, in a statement.

This model is a direct response to a well-known challenge in medical innovation: the "valley of death," where promising early-stage discoveries often languish due to a lack of funding and operational expertise. By creating a structured framework for collaboration, the partnership aims to de-risk investment and shorten development timelines. Revival’s strategy often involves a "build-to-buy" approach, where they partner with strategic acquirers from the outset, creating a clear path to market for successful innovations. This hands-on method, which leverages a team of experienced operators beyond just providing capital, is well-suited to navigate the regulatory and market hurdles inherent in the MedTech sector.

Bolstering a Thriving Ecosystem

This collaboration does not exist in a vacuum; it serves as a powerful new engine within MUSC's already formidable innovation ecosystem. The university has a proven track record of translating research into real-world impact, having spun out more than 50 active companies over the past five years. This new partnership is designed to complement and enhance existing infrastructure, which includes the Zucker Institute for Innovation Commercialization (ZI), the university's technology transfer arm, and 1824 Health Ventures, its dedicated seed capital fund.

The partnership provides a clearer, more direct pathway for MUSC-originated medical device concepts to secure the later-stage capital and industry alignment needed for full-scale development and market launch. It formalizes the bridge between the university's scientific discovery pipeline and the private capital needed to carry those discoveries forward.

“This collaboration reflects MUSC’s commitment to advancing innovation that improves patient care and health outcomes,” said David J. Cole, M.D., FACS, president of MUSC. “By working closely with Revival Healthcare Capital, our clinicians and researchers can help evaluate and inform the development of promising medical technologies, strengthening the pathway from clinical insight to real‑world impact.”

From the Lab to the Bedside: Impact on Patient Care

The ultimate beneficiary of this accelerated innovation pipeline is the patient. By shortening the typically long and arduous development cycle for new medical devices, the partnership promises to deliver cutting-edge solutions to patients more quickly. The direct involvement of MUSC's frontline clinicians ensures that the technologies being developed are not just novel, but are also designed to solve real-world clinical problems and address unmet patient needs.

This clinical validation is a cornerstone of the agreement. MUSC leaders may serve as advisors to Revival's portfolio companies, providing invaluable feedback to refine product design and ensure that new devices are safe, effective, and seamlessly integrated into clinical workflows. This close collaboration between innovators, investors, and end-users is critical for developing technologies that truly make a difference in patient outcomes and quality of life.

“By combining Revival’s flexible capital model and operational capabilities with MUSC’s strong collaboration across patient care, research and education, we believe this partnership can advance technologies that address unmet patient needs,” Pope noted.

Fueling South Carolina's Economic Engine

Beyond its immediate impact on healthcare, the MUSC-Revival partnership is poised to be a significant catalyst for economic growth in South Carolina. MUSC is already an economic juggernaut for the state, contributing an estimated $10.1 billion to its annual economy and supporting over 52,000 jobs, many of which are high-wage positions.

This new initiative is set to amplify that impact. By fostering the growth of high-value MedTech companies, the partnership will help build upon the state’s burgeoning life sciences sector, which already includes over 1,000 companies. The collaboration is expected to attract further follow-on capital into the region, create more high-quality jobs, and solidify South Carolina's reputation as an emerging hub for medical innovation. The direct pathway for MUSC's homegrown innovations to receive funding and operational support can help ensure that the economic benefits of these discoveries remain within the state.

The partnership represents a forward-thinking strategy that leverages institutional strengths to create a whole greater than the sum of its parts. By aligning academic rigor, clinical expertise, and savvy investment, MUSC and Revival are not only building a new model for MedTech development but are also investing in a healthier and more prosperous future for South Carolina and beyond.